U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493109) titled 'Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP' on March 20.
Brief Summary: To evaluate the efficacy and safety of chidamide monotherapy as maintenance treatment in patients with diffuse large B-cell lymphoma (DLBCL) and HBV infection following initial response to R-CHOP therapy, and to provide evidence for the clinical application of chidamide.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention:
DRUG: Chidamide
Chidamide is administered at a dose of 20 mg (4 tablets) twice weekly, i.e., on Days 1, 4, 8...